Exploring the effect of rosuvastatin on AGE-RAGE pathway concerning its cardioprotective potential

Cardiovascular diseases encompass several illnesses, including acute coronary syndrome.Advanced glycation end products (AGEs) are produced through the non-enzymatic glycation and oxidation of proteins, lipids and nucleic acids.Rosuvastatin, a drug with multiple pleiotropic characteristics, has been studied for its cardioprotective effects in isoproterenol-induced myocardial injury and the role it plays in altering AGE and contributing to cardiac damage.The research involved administering a daily dose of 10 mg/kg of rosuvastatin orally to male rats for four weeks, followed by the administration of isoproterenol (85 mg/ kg, subcutaneously) on the 29 th and 30 th days to induce cardiac damage.On the 31 st day, rats were subjected to euthanasia and samples were collected.The administration of isoproterenol resulted in an increase in the level of oxidative stress parameters.As a result of heart injury, advanced glycation end products were observed to increase.The AGE-RAGE cascade also had a detrimental effect on the echocardiogram of the rat heart.According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by an array of parameters.